Ennature Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -16.22%
- Ebitda -16.22%
- Net Worth -68.25%
- Total Assets -57.53%
About Ennature Bio Pharma
Ennature Bio Pharma Private Limited (EBPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 October 2021 (Three years and four months 2 days old ). Its registered office is in Dehradun, Uttarakhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shashi Shukla, Bhupendar Singhal, and Manish Pant serve as directors at the Company.
Company Details
-
Location
Dehradun, Uttarakhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290UR2021PTC013005
-
Company No.
013005
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Oct 2021
-
Date of AGM
11 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Ennature Bio Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Pant
|
Director | 01-Oct-2021 | Current |
|
Shashi Shukla
|
Director | 01-Oct-2021 | Current |
|
Bhupendar Singhal
|
Director | 01-Oct-2021 | Current |
Financial Performance of Ennature Bio Pharma.
Ennature Bio Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 16.22% decrease in profit. The company's net worth observed a substantial decline by a decrease of 68.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ennature Bio Pharma?
In 2023, Ennature Bio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Igl Spirits LimitedShashi Shukla, Bhupendar Singhal and 1 more are mutual person
-
Igl Chemicals And Services Private Limited
Shashi Shukla, Bhupendar Singhal and 1 more are mutual person
-
Gida Cetp Foundation
Shashi Shukla is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ennature Bio Pharma?
Ennature Bio Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ennature Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ennature Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.